Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response

被引:9
作者
Chaudhary, Varun [1 ]
Brent, Michael [2 ]
Lam, Wai-Ching [2 ]
Devenyi, Robert [2 ]
Teichman, Joshua [1 ]
Mak, Michael [2 ]
Barbosa, Joshua [1 ]
Kaur, Harneel [1 ]
Carter, Ronald [4 ]
Farrokhyar, Forough [3 ]
机构
[1] McMaster Univ, St Josephs Healthcare Hamilton, Hamilton Reg Eye Inst, Div Ophthalmol,Dept Surg, Hamilton, ON, Canada
[2] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[3] McMaster Univ, Dept Surg, Hamilton, ON, Canada
[4] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
关键词
Genetics; Visual acuity; Age-related macular degeneration; RANIBIZUMAB TREATMENT; CFH; POLYMORPHISM; DELETION; VARIANT; Y402H; PHARMACOGENETICS; SUSCEPTIBILITY; ASSOCIATION; THERAPY;
D O I
10.1159/000446819
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of >= 15 letters at the 6-month endpoint after adjusting for potential confounders. Results: CFH haplotypes were associated with a gain of letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of >= 15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion: CFH is implicated in nAMD patient treatment response to ranibizumab. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:88 / 94
页数:7
相关论文
共 23 条
[1]   Mitochondrial DNA Polymorphism A4917G Is Independently Associated with Age-Related Macular Degeneration [J].
Canter, Jeffrey A. ;
Olson, Lana M. ;
Spencer, Kylee ;
Schnetz-Boutaud, Nathalie ;
Anderson, Brent ;
Hauser, Michael A. ;
Schmidt, Silke ;
Postel, Eric A. ;
Agarwal, Anita ;
Pericak-Vance, Margaret A. ;
Sternberg, Paul, Jr. ;
Haines, Jonathan L. .
PLOS ONE, 2008, 3 (05)
[2]   Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration [J].
Despriet, Dominiek D. G. ;
Klaver, Caroline C. W. ;
Witteman, Jacqueline C. M. ;
Bergen, Arthur A. B. ;
Kardys, Isabella ;
de Maat, Moniek P. M. ;
Boekhoorn, Sharmila S. ;
Vingerling, Johannes R. ;
Hofman, Albert ;
Oostra, Ben A. ;
Uitterlinden, Andre G. ;
Stijnen, Theo ;
van Duijn, Cornelia M. ;
de Jong, Paulus T. V. M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (03) :301-309
[3]  
Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
[4]   Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA [J].
Fritsche, Lars G. ;
Loenhardt, Thomas ;
Janssen, Andreas ;
Fisher, Sheila A. ;
Rivera, Andrea ;
Keilhauer, Claudia N. ;
Weber, Bernhard H. F. .
NATURE GENETICS, 2008, 40 (07) :892-896
[5]   Ranibizumab Treatment in Age-Related Macular Degeneration: A Meta-Analysis of One-Year Results [J].
Gerding, H. .
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2014, 231 (04) :427-431
[6]   Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) [J].
Hagstrom, Stephanie A. ;
Ying, Gui-shuang ;
Pauer, Gayle J. T. ;
Sturgill-Short, Gwen M. ;
Huang, Jiayan ;
Callanan, David G. ;
Kim, Ivana K. ;
Klein, Michael L. ;
Maguire, Maureen G. ;
Martin, Daniel F. .
OPHTHALMOLOGY, 2013, 120 (03) :593-599
[7]  
Holz FG, 2016, BR J OPHTHALMOL
[8]   A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration [J].
Hughes, Anne E. ;
Orr, Nick ;
Esfandiary, Hossein ;
Diaz-Torres, Martha ;
Goodship, Timothy ;
Chakravarthy, Usha .
NATURE GENETICS, 2006, 38 (10) :1173-1177
[9]  
Klein R, 1998, AM J EPIDEMIOL, V147, P103
[10]   Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein [J].
Laine, Matti ;
Jarva, Hanna ;
Seitsonen, Sanna ;
Haapasalo, Karita ;
Lehtinen, Markus J. ;
Lindeman, Nina ;
Anderson, Don H. ;
Johnson, Patrick T. ;
Jarvela, Irma ;
Jokiranta, T. Sakari ;
Hageman, Gregory S. ;
Immonen, Ilkka ;
Meri, Seppo .
JOURNAL OF IMMUNOLOGY, 2007, 178 (06) :3831-3836